<DOC>
	<DOCNO>NCT03030612</DOCNO>
	<brief_summary>The purpose Phase I/II study investigate safety tolerability ( Phase I ) efficacy/clinical benefit ( Phase II , proof-of-concept ) ARGX-110 combination standard dose azacytidine ( AZA ) subject previously untreated acute myeloid leukemia ( AML ) high risk myelodysplastic syndrome ( MDS ) eligible AZA treatment .</brief_summary>
	<brief_title>ARGX-110 With AZA AML High Risk MDS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1 . Signed ICF indicate understanding purpose , risk , procedure require study willingness ability participate study 2 . AML high risk MDS ( refractory anemia excess blast transformation ; RAEB T ) ( accord 2008 World Health Organization ( WHO ) classification definition ≥ 20 % blast ) Note : Subjects rescreened exclude base blast count previously 3 . Age ≥ 18 year 4 . Expected life expectancy ≥ 3 month , discretion investigator 5 . ECOG performance status 0 , 1 , 2 1 . Prior concurrent malignancy , except follow : adequately treat basal cell squamous cell skin cancer , cancer subject diseasefree 2 year 2 . Any previous cancer chemo radiotherapy ( exception hydroxyurea/Litalir® leukocyte control discontinue first day AZA , local radiation therapy , therapy basal cell carcinoma skin ) 3 . Treatment investigational product within 4 week first administration ARGX110 4 . Abnormal organ function define follow ( single parameter fulfill condition ) : aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 3 x upper limit normal ( ULN ) ; case liver infiltration AML , AST and/or ALT &gt; 5 x ULN Alkaline phosphatase ( AP ) &gt; 2.5 x ULN , case liver infiltration AML , AP &gt; 5 x ULN Serum ( total ) bilirubin &gt; 1.5 x ULN ; case liver infiltration AML , serum ( total ) bilirubin &gt; 5 x ULN Serum creatinine &gt; 2.5 x ULN GFR ( MDRD ) &lt; 40 mL/min subject creatinine level normal limit . 5 . Use immunesuppressive agent past 4 week first administration ARGX110 Day 14 . For regular use systemic corticosteroid , subject may include stepwise discontinuation free steroid minimum 5 day first administration ARGX110 6 . Any known active chronic infection , include human immunodeficiency virus ( HIV ) hepatitis B C virus infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>